SCHEMBL1067424

SCHEMBL1067424

CCOC(=O)/C=C(/C)Oc1cccc(OCC)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
GLA P06280 1/20 0.38
LMNA P02545 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
ATM Q13315 1/20 0.37
GPR35 Q9HC97 1/20 0.37
RAB9A P51151 2/20 0.36
RORC P51449 1/20 0.35
PTPN1 P18031 1/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
KDM4E B2RXH2 2/20 0.35
POLB P06746 1/20 0.35
PKM P14618 1/20 0.35
GALK1 P51570 1/20 0.35
CCR6 P51684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1067425 1.00 MAPT (0.38) MAPTL3MBTL1GLALMNASMN1; SMN2
SCHEMBL1066872 0.89 MAPT (0.41) MAPTL3MBTL1LMNAGPR35KMT2A
SCHEMBL1066869 0.89 MAPT (0.41) MAPTL3MBTL1LMNAGPR35KMT2A
SCHEMBL1066360 0.88 MAPT (0.47) MAPTL3MBTL1LMNASMN1; SMN2GPR35
SCHEMBL1066358 0.88 MAPT (0.47) MAPTL3MBTL1LMNASMN1; SMN2GPR35
SCHEMBL1066356 0.88 MAPT (0.47) MAPTL3MBTL1LMNASMN1; SMN2GPR35
SCHEMBL1068919 0.86 L3MBTL1 (0.49) MAPTL3MBTL1GLALMNAATM
SCHEMBL1068916 0.86 L3MBTL1 (0.49) MAPTL3MBTL1GLALMNAATM
SCHEMBL1068918 0.86 L3MBTL1 (0.49) MAPTL3MBTL1GLALMNAATM
SCHEMBL1067215 0.84 L3MBTL1 (0.38) MAPTL3MBTL1GLALMNAATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 MAPT 4151/4885L3MBTL1 4431/4885GLA 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.